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ABSTRACT 
 
Microtubule inhibitors such as Vinblastine and Paclitaxel are chemotherapy agents that activate the mitotic spindle 
checkpoint, arresting cells in mitosis and leading to cell death. The pathways that connect mitotic arrest to cell death 
are not well characterized. We developed a mammalian cell-based cDNA cloning method to isolate proteins and 
protein fragments whose expression inhibits colony formation in the presence of microtubule inhibitors. 
Understanding how these proteins impact cellular responses to microtubule drugs will lead to better understanding of 
the biochemical pathways connecting mitotic arrest and cell death in mammalian cells and may provide novel targets 
that can enhance microtubule inhibitor-mediated chemotherapy. 
 
 
INTRODUCTION 
 
Microtubule inhibitors such as Taxanes (e.g. Taxol) and 
Vinca Alkaloids (e.g. Vinblastine, Vincristine) are 
commonly used chemotherapy drugs (1-3). In clinically 
relevant doses (e.g. 5-200nM for Taxol (4)), they perturb 
normal microtubule dynamics by hyperstabilization or 
by destabilization of microtubules and activate the 
mitotic spindle checkpoint (5-7). The spindle checkpoint 
causes extended mitotic arrest. Cell death ensues either 
during the mitotic arrest or after cells exit mitosis 
without normal chromosome segregation (sometimes 
called adaptation or mitotic slippage) (4, 8). The signal 
transduction pathways by which microtubule inhibitors 
and other mitotic inhibitors lead to cell death remain to 
be clarified (8, 9). 
 
In spite of the apparent linkage, correlation between 
the function of the spindle checkpoint and microtubule 
inhibitor-mediated cell death remains elusive. Spindle 
checkpoint proteins are essential for survival in  
 
mammalian cells (10-12), thus researchers have used 
either cancer cells with weakened checkpoint function or 
cultured cells with conditional expression of mutant 
checkpoint proteins or siRNA to investigate the 
correlation. Some cancer cells with weakened spindle 
checkpoint function were reported to show elevated 
sensitivity to microtubule inhibitors (13). Other studies 
have shown that cells with partial loss of the checkpoint 
function are resistant to microtubule destabilizing drugs 
such as nocodazole but not to microtubule stabilizing 
drugs such as Taxol. These data suggest that a partial 
loss of spindle checkpoint may decrease cell death, and 
there are differences in cellular response dependent on 
the type of microtubule challenge (14).  
 
Most of the proteins that participate in the central 
pathway of the spindle checkpoint were identified in 
genetic screens in budding yeast. Recent studies with 
mammalian cells suggest that proteins typically 
associated with the spindle checkpoint signalling 
pathway also have additional functions or are regulated     
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via distinct pathways. Mice haploinsufficient in BubR1 
(15) or in both Bub3 and Rae1 (16) show premature 
aging-associated phenotypes, associated with cellular 
senescence involving the p53 and p16 pathways. After 
prolonged mitotic arrest of certain mammalian cell lines 
by microtubule drugs, Bub1 and BubR1 are degraded by 
caspases thus inducing exit from M phase without 
mitosis (17, 18). These examples reveal signalling 
pathways that may not be represented in yeast. Our goal 
was to identify additional proteins and biochemical 
pathways that modulate cellular responses to activation 
of the mitotic spindle checkpoint in mammalian cells. 
With this, we designed a mammalian cell-based cDNA 
screening method to identify modulators of the spindle 
checkpoint and subsequent apoptosis and/or senescence 
pathways. In particular we hoped to identify proteins 
that participated in pathways connecting cell death with 
microtubule drug challenge. The identification of these 
proteins would fill a significant gap in our current 
knowledge relating the mitotic spindle checkpoint and 
cell death, and potentially point to novel targets for 
cancer chemotherapy. 
 
RESULTS AND DISCUSSION 
 
The protocol consists of two separate steps; cDNA 
selection and validation. The first half of the process is 
summarized in Figure 1. We transfected cells with a 
cDNA library and selected for cells that rapidly initiate 
apoptosis or escape mitotic arrest (mitotic slippage) 
when treated with microtubule inhibitor. Although 
mitotic slippage itself does not necessarily mean the 
escaped cell will die, it does suggest that expression of 
the exogenous cDNA has compromised normal spindle 
checkpoint function. To be detected in our screen, 
expression of the cDNA might affect the microtubule 
inhibitor-mediated cell death/senescence pathway either 
in a dominant or dominant-negative manner.  
 
The cDNA expression cloning method took advantage of 
the fact that mammalian cultured cell lines (e.g. HeLa, 
COS7) change their morphology and adhesiveness 
during mitosis and apoptosis. During interphase the cells 
adhere tightly to culture substrate. In mitosis, cells of 
most lines round up and can be detached easily by 
mechanical agitation. At mitotic exit, cells reattach and 
flatten on the substrate. We noted that mitotic cells 
undergoing apoptosis also exhibited increased adherence 
to the culture substrate compared with healthy mitotic 
cells, although the adherence is weaker than that of 
healthy interphase cells. This allowed us to select for cells 
containing plasmids whose expression caused increased 
mitotic exit and/or apoptosis in cells arrested in mitosis 
with microtubule inhibitors (Fig. 1). Weaver and 
Cleveland (2005) categorized possible outcomes after 
antimitotic drug treatment to five phenotypes; (a) 
chronic mitotic arrest, (b) mitotic death, (c) survival after 
mitotic exit without growth (senescence) , (d) survival 
after mitotic exit with continuing growth, and (e) cell 
death after mitotic exit (8). Our selection step would 
capture phenotypes (b), (c), (d) and (e), whereas our 
validation step (described later) would select against 
cDNAs that cause phenotype (d), leaving cDNAs that 
may be involved in the microtubule inhibitor-mediated 
cell death or senescence pathways. 
 
 
Fig. 1: Mammalian cell-based cDNA expression cloning protocol for cells 
that adhere to the substrate after overriding the mitotic spindle 
checkpoint or induction of apoptosis in the continued presence of 
microtubule inhibitor. See text for detailed description. 
 
We transfected COS7 cells with a commercial human 
cDNA library contructed with pEXP1 plasmid (Clontech) 
(Step 1). We then allowed expression for 12-24 hours 
(Step 2). This time was determined to be optimal for 
reducing integration of the plasmid DNA into the host     
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genome thus facilitating subsequent recovery of the 
plasmid from the mammalian cells. The cells were rinsed 
extensively to remove untransfected plasmid and dead 
or dying cells. The cultures were then treated with 
microtubule inhibitor nocodazole (100ng/ml) to induce 
mitotic arrest. COS7 cells have a robust spindle 
checkpoint and, in the presence of microtubule inhibitor, 
remain arrested in mitosis for at least 18 hours. One hour 
after the initial treatment with nocodazole and every 
hour afterward for 13 additional hours we gently 
dislodged the rounded mitotic cells and incubated them 
on new plates in medium with nocodazole for 2 to 14 
hours (Step 3). In this manner we collected cells as they 
entered mitosis thus avoiding cells in which expression 
of the transfected insert led to cell cycle arrest elsewhere 
during the cell cycle. One of three outcomes occurs 
during continued incubation in nocodazole: (i) cells 
remain arrested in mitosis and stay rounded, (ii) cells exit 
mitosis, flatten, and attach to the plate, and (iii) cells 
initiate apoptosis and adhere to the plate (Step 4). We 
washed the plates with PBS to remove rounded mitotic 
cells (Step 5). We added DNAzol reagent (Invitrogen) to 
the plates to recover the plasmids from the remaining 
adherent cells. Smaller sized DNA including episomic 
plasmid was recovered after ethanol precipitation. We 
used the recovered DNA to transform high-efficiency 
competent bacteria and recovered the plasmids as 
bacterial colonies (Step 6). In the first round of all six 
steps, starting from approximately three million COS7 
transfectants, we obtained several hundred bacterial 
colonies and recovered plasmids from the bacterial 
colonies. We pooled the recovered plasmids and 
repeated the transfection of COS7 cells and selection 
protocol once more to enrich for plasmids encoding 
proteins that reliably induce mitotic exit or apoptosis in 
the presence of nocodazole (modified “cycle cloning”: 19-
21). In the second round, starting from approximately 
one million COS7 transfectants, we obtained 58 bacterial 
colonies. We recovered plasmids from individual 
colonies, and sequenced the inserts. Of these, 34 returned 
interpretable data. Seven plasmids appeared to have an 
altered structure, possibly because of recombination or 
deletion events that occurred during the process. 
 
In the second half of the procedure for validation of 
isolated cDNAs, we established cell lines that express the 
cDNA stably so that we could test their microtubule 
inhibitor sensitivity. This step was included because the 
result from transient expression experiments might be 
affected by experimental variables such as transfection 
efficiency. By establishing stable lines we could isolate 
proteins whose expression was important only in cellular 
response to microtubule drug treatment. It eliminated 
cDNAs that simply expressed proteins that induced 
apoptosis in the absence of the microtubule drugs. In this 
w a y  w e  b i a s e d  o u r  s c r e e n  t o  f i n d  c o m p o n e n t s  o f  t h e  
signalling pathways linking spindle checkpoint 
activation and mitotic cell death in mammalian cells. 
 
 
Fig. 2: (A) Elevated microtubule inhibitor sensitivity in HeLa cell derived 
lines stably expressing cDNA identified in the screen. The top row is the 
control cell line (HeLa). The second and third rows are cells stably 
expressing two different cDNA fragments identified in the screen (HeLa-
SC3; HeLa-SC29). One thousand cells were plated on 6cm plate, treated 
with indicated dose of nocodazole and incubated for eight days. The 
medium was replenished at four days. The cells were fixed/stained with 
0.5% Methylene blue in 50% Ethanol for 20 minutes, then rinsed and 
dried. (B) HeLa-SC3 cells show elevated sensitivity to Monastrol and 
HR22C16, kinesin inhibitors that also activate spindle checkpoint and 
cause mitotic arrest. Four hundred cells were incubated with indicated 
dose of drug for eight days and fixed/dried.     
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We generated lines of HeLa cells in which the inserts 
were stably integrated into the host cell genome, 
constitutively expressed under the CMV promoter, along 
with the puromycin resistance gene. Among 34 
candidate plasmids, 20 yield stable HeLa integrants after 
3 weeks of puromycin (0.2-0.5 µg/ml) selection. We 
tested their sensitivity to microtubule inhibitors with a 
colony formation assay. Seven of the twenty HeLa-based 
cell lines showed enhanced microtubule inhibitor 
sensitivity, and results of two are shown as examples 
(Fig. 2A). None of the seven lines showed elevated 
sensitivity to VM26 (teniposide), a topoisomerase II 
inhibitor. For control purposes we established 48 
integrant cell lines from the original cDNA library 
without selection. None among the 48 lines showed 
elevated sensitivity to microtubule inhibitors. Thus the 
enrichment for cDNAs coding for proteins modulating 
cellular responses to microtubule drug treatment was 
significant. Enhancement of substrate attachment in the 
presence of nocodazole was tested for representative cell 
lines HeLa-SC3 and HeLa-SC29, resulting 2.5-22 times 
higher substrate attachment.  Detailed description and 
characterization of one of the candidate cDNA and the 
integrant, shown as HeLa-SC3, is reported in ref. 22. The 
cDNA encodes a dominant-negative form of TRIP1, a 19S 
proteasome regulatory subunit. 
 
Although microtubule inhibitors are potent anticancer 
drugs, they also have significant side effects such as 
neurotoxicity. A new generation of mitosis-targeting 
drugs are being developed, including drugs such as 
Monastrol and HR22C16 that inhibit mitotic kinesins (8, 
23). As expected, HeLa-SC3 cells are also sensitive to 
Monastrol and HR22C16 that activate the spindle 
checkpoint without microtubule disruption (Fig. 2B). 
Thus our selection method should prove equally useful 
in identifying proteins that modulate cellular responses 
to non-microtubule, anti-mitotic drugs. 
 
Lastly, our protocols should be equally applicable to the 
screening of libraries of plasmids encoding hairpin 
RNAs that generate siRNA inhibitors of protein 
expression. 
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PROTOCOLS 
 
(1) Protocol for cDNA selection 
 
Reagents 
  
•  HeLa or COS7 cells 
•  Culture medium: DMEM (Dulbecco’s Modified Eagle Medium) (Gibco, cat. No 11965-092) supplemented with 
10% Fetal Calf Serum, 1% MEM Nonessential Amino Acid solution (Gibco), 20mM HEPES(pH7.2), 1% Penicillin- 
streptomycin (Gibco cat. No 15140-122), 1mM sodium pyruvate (Sigma) 
•  Phosphate Buffered Saline (PBS)  
•  FuGene6 transfection reagent (Roche) 
•  cDNA expression library. We used Human Testis ClonCapture cDNA Library (ClonTech) 
•  15cM tissue culture plate 
•  37 degree incubator (5% CO2) 
•  DNAzol reagent (BibcoBRL) 
•  High-efficiency competent bacteria (e.g. UltraMax DH5alpha-FT (Invitrogen)) 
•  DNA preparation kit (e.g. Qiafilter midi kit, Qiagen) 
•  Other common equipment and reagents for cell culture 
 
Note: We recommend using SV40 origin-containing library with COS7 cells to allow plasmid amplification inside the 
host cells and to increase the chance of plasmid recovery. It is not a requirement, however. 
 
1.  Plate HeLa (or COS7) cells to three 15cM plates 
2.  Transfect the cells (60-70% confluent) with cDNA library using FuGene 6. Use 10-15ug DNA/plate. 
3.  Incubate 12-24 hours. 
4.  Rinse the plate with 20ml PBS/plate five times to remove dead cells and untransfected DNA. 
5.  Add 15ml/plate fresh medium containing nocodazole (100ng/ml). This is hour zero. 
6.  At hour one, shake off rounded mitotic cells, transfer the medium with round (mitotic) cells to a 15cM plate and 
incubate. Add fresh nocodazole containing media to the original plates. Repeat this step every hour, up to hour 14. 
Then discard original three plates. 
7.  At hour 16, rinse plates that hold transferred round cells with PBS (30ml/plate). 
8.  Add 30ml DNAzol reagent. Process all 14 plates with the 30ml of DNAzol. 
9.  (Follow DNAzol protocol for DNA recovery) Add 15ml 100% Ethanol to DNAzol solution. Centrifuge and 
precipitate DNA. Rinse the DNA pellet with 75% Ethanol/water twice. Dissolve the pellet in water. 
10.  Use the DNA to transform high-efficiency competent bacteria. We used UltraMax DH5alpha-FT (GibcoBRL). 
11.  When transformed colonies emerge, collect and culture the bacteria with appropriate antibiotics, then recover 
plasmid. The resulting plasmid should be a mixture of candidate cDNA-containing plasmids. 
12.  Return to the beginning of this procedure and repeat the process. Repeating the process would enrich plasmid 
with “positive” cDNA and reduce false positives. 
13.  Once you obtain bacterial transformants after the second round, pick at least 50 colonies, recover plasmids 
individually and sequence. Also check the integrity of the recovered plasmids by agarose gel electrophoresis. 
Although the screening time is adjusted to be minimal, plasmid recombination occurs frequently within 
mammalian cells. 
 
(2) Protocol for secondary screen (validation step) 
 
1. Establish integrants of candidate cDNA by selection with resistance to marker drug. 
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Reagents 
 
•  HeLa cells 
•  Culture medium: DMEM (Dulbecco’s Modified Eagle Medium) (Gibco, cat. No 11965-092) supplemented with 
10% Fetal Calf Serum, 1% MEM Nonessential Amino Acid solution (Gibco), 20mM HEPES (pH7.2), 1% Penicillin-
streptomycin (Gibco cat. No 15140-122), 1mM sodium pyruvate (Sigma) 
•  Candidate cDNA plasmids, at least 1 ug for each transfection 
•  FuGene6 transfection reagent (Roche) 
•  6-well tissue culture plate 
•  37 degree incubator (5% CO2) 
•  Puromycine (Sigma), or appropriate selection drug 
•  Other common equipment and reagents for cell culture 
 
1.  Transfect 30-50% confluent HeLa cells in 6-well plate with each candidate plasmid using FuGene6 (Example: if 
you have 50 candidates, you’ll perform 50 independent transfections). 
2.  48 hours after transfection, add appropriate selective reagent to the culture, which will select transfectants that 
stably express the cDNA. The cDNA library we used contained puromycin resistance under an internal ribosome 
entry site thus was coexpressed with the cDNA. We used 0.2-0.5 ug/ml puromycin. With successful selection, you 
should observe massive cell death of nontransfected cells in 5 days. 
3.  Replace culture medium with drug every 3 days. After 2-3 weeks, surviving colonies will emerge. 
4.  Pool the surviving colonies to average the effect of varying expression. 
 
Optional: you can pick up colonies, verify and quantify cDNA expression by RT-PCR and select representative 
colonies. However, this option will significantly increase the labour. Given the number of the candidates to be 
processed, we suggest using simple protocol for now. Clone isolation, if desired, can be done after candidates for 
positive are isolated in next step. 
 
2. Test nocodazole sensitivity of the transfectants and determine “positive.” 
 
We used the colony formation assay shown in Figure 2, which takes about 9 days. 
 
Reagents 
 
•  HeLa cells and candidate integrants from above 
•  Culture medium: DMEM (Dulbecco’s Modified Eagle Medium) (Gibco, cat. No 11965-092) supplemented with 
10% Fetal Calf Serum, 1% MEM Nonessential Amino Acid solution (Gibco), 20mM HEPES (pH 7.2), 1% Penicillin-
streptomycin(Gibco cat. No 15140-122), 1mM sodium pyruvate (Sigma) 
•  Phosphate Buffered Saline (PBS)  
•  24-well tissue culture plate 
•  37 degree incubator (5% CO2) 
•  Nocodazole (stock: 1mg/ml in DMSO) 
•  0.5% Methylene blue in 50% Ethanol/water 
•  Other common equipments and reagents for cell culture 
 
1.  Prepare culture for the candidate integrants along with controls. 
2.  Trypsinize cells to detach cells. Count cells and dilute to 500 cells/ml in 15ml. 
3.  Plate the diluted culture to 12 wells in 24-well plate, 1ml/well.     
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4.  24 hours later, add nocodazole to the culture in 6 concentrations (final concentrations; 0, 2.5, 5, 7.5, 10, 12.5 ng/ml). 
Use two wells for each concentration for duplicate. This is day one. 
5.  On day four, add 1ml medium with defined concentration of nocodazole to all wells. 
6.  On day eight, discard medium and add 200 ul of 0.5% Methylene blue solution to each well. Keep the plate on 
rocking shaker for 20 minutes. 
7.  Discard Methylene blue solution. Rinse wells by water twice, then dry. 
8.  Compare colony formation between control and the cells to be tested. Count cell lines with poor colony formation 
and the expressed cDNA as “positive.” Optional: quantify the results using imaging analysis software. 
 
To test taxol sensitivity, we suggest using following set of concentrations: 0, 0.5, 1, 1.25, 1.5, 2 nM. 